恒瑞醫藥：子公司卓託奇拜單抗注射液上市申請獲受理

財中社

09/03

9月3日，恒瑞醫藥（600276/01276）發布公告，子公司廣東恒瑞醫藥有限公司收到國家藥監局下發的《受理通知書》，公司的卓託奇拜單抗注射液藥品上市許可申請獲國家藥監局受理。　　卓託奇拜單抗注射液用於治療外用藥控制不佳或不適合外用藥治療的成人中重度特應性皮炎。　　公告提到，SHR-1819 注射液是公司自主研發的一種靶向人IL-4Rα的重組人源化單克隆抗體，能夠同時阻斷IL-4和IL-13的信號...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2664878306"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664878306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664878306?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-03 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664878306","market":"sh","top_or_hot":-1,"title":"恒瑞醫藥：子公司卓託奇拜單抗注射液上市申請獲受理","media":"財中社","content":"<div>\n<p>9月3日，恒瑞醫藥（600276/01276）發布公告，子公司廣東恒瑞醫藥有限公司收到國家藥監局下發的《受理通知書》，公司的卓託奇拜單抗注射液藥品上市許可申請獲國家藥監局受理。　　卓託奇拜單抗注射液用於治療外用藥控制不佳或不適合外用藥治療的成人中重度特應性皮炎。　　公告提到，SHR-1819 注射液是公司自主研發的一種靶向人IL-4Rα的重組人源化單克隆抗體，能夠同時阻斷IL-4和IL-13的信號...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609033864116562.html\">網頁鏈接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞醫藥：子公司卓託奇拜單抗注射液上市申請獲受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞醫藥：子公司卓託奇拜單抗注射液上市申請獲受理\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">財中社</strong><span class=\"h-time small\">2026-09-03 17:08</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>9月3日，恒瑞醫藥（600276/01276）發布公告，子公司廣東恒瑞醫藥有限公司收到國家藥監局下發的《受理通知書》，公司的卓託奇拜單抗注射液藥品上市許可申請獲國家藥監局受理。　　卓託奇拜單抗注射液用於治療外用藥控制不佳或不適合外用藥治療的成人中重度特應性皮炎。　　公告提到，SHR-1819 注射液是公司自主研發的一種靶向人IL-4Rα的重組人源化單克隆抗體，能夠同時阻斷IL-4和IL-13的信號...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609033864116562.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://finance.eastmoney.com/a/202609033864116562.html\">財中社</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131003.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609033864116562.html","article_id":"2664878306","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864116562.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2664878306","pubTimestamp":1788426480,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"9月3日，恒瑞醫藥（600276/01276）發布公告，子公司廣東恒瑞醫藥有限公司收到國家藥監局下發的《受理通知書》，公司的卓託奇拜單抗注射液藥品上市許可申請獲國家藥監局受理。卓託奇拜單抗注射液用於治療外用藥控制不佳或不適合外用藥治療的成人中重度特應性皮炎。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0196":"行业龙头","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0239":"医药制造","BK1191":"制药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","IPOS":"Renaissance International IPO ETF","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0188":"融资融券","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK0012":"证金概念","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","01276":"恒瑞医药","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0028":"国家队","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0060":"抗癌","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC"},"translate_title":"Hengrui Medicine: Subsidiary's marketing application for zolokibimab injection accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"IPOS":1.5,"01276":1.5},"content_text":"9月3日，恒瑞醫藥（600276/01276）發布公告，子公司廣東恒瑞醫藥有限公司收到國家藥監局下發的《受理通知書》，公司的卓託奇拜單抗注射液藥品上市許可申請獲國家藥監局受理。　　卓託奇拜單抗注射液用於治療外用藥控制不佳或不適合外用藥治療的成人中重度特應性皮炎。　　公告提到，SHR-1819 注射液是公司自主研發的一種靶向人IL-4Rα的重組人源化單克隆抗體，能夠同時阻斷IL-4和IL-13的信號傳導，在研適應症覆蓋特應性皮炎、結節性癢疹、過敏性鼻炎等多種2型炎症疾病。　　2026年中期，恒瑞醫藥實現收入154.56億元，歸母淨利潤44.65億元。（文章來源：財中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}